Crohn’s disease: Combination study with guselkumab and golimumab in Crohn’s disease (DUET-CD)

ClinicalTrials.gov ID: NCT05242471
Sponsor: Janssen Research & Development, LLC

Official title:
Randomized, double-blind, active- and placebo-controlled, multicenter, phase 2b parallel-group study to evaluate the efficacy and safety of induction and maintenance therapy with guselkumab and golimumab in patients with moderately to severely active Crohn’s disease.

Study overview:
The aim is to evaluate the efficacy of JNJ-78934804 at week 48 compared to guselkumab and golimumab.